前列地尔治疗慢性肾功能衰竭的临床效果
|
摘要
目的研究前列地尔治疗慢性肾功能衰竭的临床效果。方法选取2016年12月～2017年12月我院收治的66例慢性肾功能衰竭患者作为研究对象,按照奇偶分组法将其分为对照组(33例)与实验组(33例)。对照组患者采用常规药物治疗,实验组患者采用前列地尔治疗。比较两组患者的治疗效果、治疗前后肾功能指标、24 h尿蛋白量、治疗前后的血液流变学指标变化。结果经过药物治疗14 d后,实验组患者的治疗总有效率为81.82%,高于对照组(63.64%),差异有统计学意义(P<0.05);实验组患者治疗后的血尿素氮(BUN)、血肌酐(SCr)等肾功能指标和24 h尿蛋白量低于治疗前,内生肌酐清除率(Ccr)高于治疗前,差异有统计学意义(P<0.05);实验组患者治疗后的BUN、SCr、等肾功能指标和24 h尿蛋白量低于对照组,Ccr高于对照组,差异有统计学意义(P<0.05);实验组患者治疗后的全血低切黏度、全血高切黏度、血细胞聚集指数、血液黏度、血细胞比容和红细胞变形指数等血液流变学指标低于治疗前,差异有统计学意义(P<0.05);实验组患者治疗后的全血低切黏度、全血高切黏度、血细胞聚集指数、血液黏度、血细胞比容和红细胞变形指数等血液流变学指标低于对照组,差异有统计学意义(P<0.05)。结论慢性肾功能衰竭患者接受前列地尔治疗,能够改善患者的肾功能和血液流变学指标,值得推广应用。
Objective To study the clinical effect of Alprostadil in the treatment of chronic renal failure(CRF). Methods Sixty-six patients with CRF admitted from December 2016 to December 2017 were enrolled as study subjects. The participants were divided into control group(n=33) and experimental group(n=33) according to the odd or even number. In the control group, conventional drug was used, while in the experimental group, Alprostadil was adopted. The therapeutic effect, renal function indicators before and after treatment, 24 h urine protein, blood rheology indicators before and after treatment were compared in the two groups. Results After 14-day drug treatment, the total therapeutic effectiveness rate of the experimental group was 81.82%,which was higher than that of control group(63.64%) with a significant difference(P<0.05). The renal function indicators such as blood urea nitrogen(BUN), serum creatinine(SCr)and 24 h urine protein after treatment in the experimental group were all lower compared with those before treatment,creatinine clearance rate(Ccr) was higher compared with before treament with significant differences(P<0.05). The renal function indicators such as BUN, SCr and 24 h urine protein after treatment in the experimental group were lower compared with those of the control group, Ccr was higher than that in the control group with statistical significance(P<0.05). The blood rheology indicators such as the whole blood low-shear viscosity,whole blood high-shear viscosity,blood cell aggregation index, blood viscosity, haematocrit, erythrocyte deformation index after treatment in the experimental group were lower compared with those before treatment(P<0.05). The above-mentioned blood rheology indicators in the experimental group after treatment were lower compared with those in the control group with statistical significance(P<0.05). Conclusion The treatment of Alprostadil in patients with CRF can improve patient′s renal function and hemorheology indicators, which is worthy of promotion and application.
Objective To study the clinical effect of Alprostadil in the treatment of chronic renal failure(CRF). Methods Sixty-six patients with CRF admitted from December 2016 to December 2017 were enrolled as study subjects. The participants were divided into control group(n=33) and experimental group(n=33) according to the odd or even number. In the control group, conventional drug was used, while in the experimental group, Alprostadil was adopted. The therapeutic effect, renal function indicators before and after treatment, 24 h urine protein, blood rheology indicators before and after treatment were compared in the two groups. Results After 14-day drug treatment, the total therapeutic effectiveness rate of the experimental group was 81.82%,which was higher than that of control group(63.64%) with a significant difference(P<0.05). The renal function indicators such as blood urea nitrogen(BUN), serum creatinine(SCr)and 24 h urine protein after treatment in the experimental group were all lower compared with those before treatment,creatinine clearance rate(Ccr) was higher compared with before treament with significant differences(P<0.05). The renal function indicators such as BUN, SCr and 24 h urine protein after treatment in the experimental group were lower compared with those of the control group, Ccr was higher than that in the control group with statistical significance(P<0.05). The blood rheology indicators such as the whole blood low-shear viscosity,whole blood high-shear viscosity,blood cell aggregation index, blood viscosity, haematocrit, erythrocyte deformation index after treatment in the experimental group were lower compared with those before treatment(P<0.05). The above-mentioned blood rheology indicators in the experimental group after treatment were lower compared with those in the control group with statistical significance(P<0.05). Conclusion The treatment of Alprostadil in patients with CRF can improve patient′s renal function and hemorheology indicators, which is worthy of promotion and application.
引文
[1]张晓燕.前列地尔对慢性肾功能衰竭患者微炎症状态的影响[J].西南国防医药,2015,25(7):716-719.
[2]徐磊,徐增山,李宏伟,等.活血益气汤联合前列地尔治疗慢性肾功能衰竭患者临床疗效观察及对营养生化指标和炎症因子水平的影响[J].国际泌尿系统杂志,2016,36(3):428-431.
[3]魏国微,丁毅,杨辉,等.前列地尔联合丹参酮Ⅱ(A)治疗老年慢性肾功能衰竭患者疗效分析[J].贵阳中医学院学报,2016,38(6):21-23.
[4]范学礼.前列地尔对慢性肾功能衰竭患者血清炎症因子水平及营养生化指标的影响[J].河南医学研究,2016,25(10):1812-1813.
[5]林李琴.前列地尔联合肾康用于糖尿病性肾病慢性肾功能衰竭的效果分析[J].医学信息,2016,29(27):89-90.
[6]陈灿.益肾化湿颗粒联合前列地尔注射液治疗慢性肾功能衰竭的临床研究[J].基层医学论坛,2016,20(13):1783-1784.
[7]陈东,王琳,刘强强,等.前列地尔联合肾康注射液治疗老年人慢性肾功能衰竭的临床效果观察[J].中国医药指南,2017,15(33):54-55.
[8]张丹丹.前列地尔联合肾康注射液治疗老年人慢性肾功能衰竭的临床疗效分析[J].中国医药指南,2017,15(26):172-173.
[9]李鹏,孟庆泽,刘德海,等.大黄灌肠汤联合前列地尔治疗慢性肾功能衰竭临床研究[J].中医学报,2017,32(1):120-123.
[10]刘改灵,陈晖,朱清,等.前列地尔对慢性肾功能衰竭患者炎症状况及肾功能的影响[J].中国实用医刊,2018,45(1):109-112.
[11]高继云.肾康联合前列地尔治疗糖尿病肾病慢性肾功能衰竭的疗效观察[J].中国医药指南,2017,15(31):216-217.
[12]崔东锋.前列地尔治疗慢性肾功能衰竭的疗效及对血清炎症因子水平的影响[J].泰山医学院学报,2017,38(9):1038-1039.
[13]王建清.参芪地黄汤联合前列地尔对慢性肾功能衰竭肾功能、炎症因子水平和血液流变学的影响[J].内蒙古中医药,2017,36(17):34-35.
[14]兰海华,王业绩.前列地尔与肾康注射液联合治疗老年慢性肾功能衰竭的临床效果观察[J].中国医药指南,2017,15(22):59-60.
[15]刘俊霞,唐昕.探讨前列地尔注射液治疗慢性肾功能衰竭患者的临床疗效[J].中国医药指南,2017,15(15):139-140.
[16]王静.前列地尔联合左卡尼汀治疗慢性肾功能衰竭合并心力衰竭患者的效果探讨[J].中国医药指南,2017,15(13):140.
[2]徐磊,徐增山,李宏伟,等.活血益气汤联合前列地尔治疗慢性肾功能衰竭患者临床疗效观察及对营养生化指标和炎症因子水平的影响[J].国际泌尿系统杂志,2016,36(3):428-431.
[3]魏国微,丁毅,杨辉,等.前列地尔联合丹参酮Ⅱ(A)治疗老年慢性肾功能衰竭患者疗效分析[J].贵阳中医学院学报,2016,38(6):21-23.
[4]范学礼.前列地尔对慢性肾功能衰竭患者血清炎症因子水平及营养生化指标的影响[J].河南医学研究,2016,25(10):1812-1813.
[5]林李琴.前列地尔联合肾康用于糖尿病性肾病慢性肾功能衰竭的效果分析[J].医学信息,2016,29(27):89-90.
[6]陈灿.益肾化湿颗粒联合前列地尔注射液治疗慢性肾功能衰竭的临床研究[J].基层医学论坛,2016,20(13):1783-1784.
[7]陈东,王琳,刘强强,等.前列地尔联合肾康注射液治疗老年人慢性肾功能衰竭的临床效果观察[J].中国医药指南,2017,15(33):54-55.
[8]张丹丹.前列地尔联合肾康注射液治疗老年人慢性肾功能衰竭的临床疗效分析[J].中国医药指南,2017,15(26):172-173.
[9]李鹏,孟庆泽,刘德海,等.大黄灌肠汤联合前列地尔治疗慢性肾功能衰竭临床研究[J].中医学报,2017,32(1):120-123.
[10]刘改灵,陈晖,朱清,等.前列地尔对慢性肾功能衰竭患者炎症状况及肾功能的影响[J].中国实用医刊,2018,45(1):109-112.
[11]高继云.肾康联合前列地尔治疗糖尿病肾病慢性肾功能衰竭的疗效观察[J].中国医药指南,2017,15(31):216-217.
[12]崔东锋.前列地尔治疗慢性肾功能衰竭的疗效及对血清炎症因子水平的影响[J].泰山医学院学报,2017,38(9):1038-1039.
[13]王建清.参芪地黄汤联合前列地尔对慢性肾功能衰竭肾功能、炎症因子水平和血液流变学的影响[J].内蒙古中医药,2017,36(17):34-35.
[14]兰海华,王业绩.前列地尔与肾康注射液联合治疗老年慢性肾功能衰竭的临床效果观察[J].中国医药指南,2017,15(22):59-60.
[15]刘俊霞,唐昕.探讨前列地尔注射液治疗慢性肾功能衰竭患者的临床疗效[J].中国医药指南,2017,15(15):139-140.
[16]王静.前列地尔联合左卡尼汀治疗慢性肾功能衰竭合并心力衰竭患者的效果探讨[J].中国医药指南,2017,15(13):140.